Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408574 | 0.95 | — | — | |
| SCHEMBL1633705 | 0.88 | CES2 (0.59) | TSHRCES2MEN1KMT2ATHRB | |
| SCHEMBL30054587 | 0.88 | CES2 (0.37) | TSHRCES2MEN1KMT2ATHRB | |
| SCHEMBL1636629 | 0.86 | CES2 (0.63) | TSHRCES2MEN1KMT2ATHRB | |
| SCHEMBL14939700 | 0.86 | CES2 (0.63) | TSHRCES2MEN1KMT2ATHRB | |
| SCHEMBL25424773 | 0.86 | CES2 (0.63) | TSHRCES2MEN1KMT2ATHRB | |
| SCHEMBL16107083 | 0.86 | CES2 (0.63) | TSHRCES2MEN1KMT2ATHRB | |
| SCHEMBL1635179 | 0.86 | CES2 (0.63) | TSHRCES2MEN1KMT2ATHRB | |
| SCHEMBL1633949 | 0.86 | CES2 (0.63) | TSHRCES2MEN1KMT2ATHRB | |
| SCHEMBL11243551 | 0.85 | CES2 (0.38) | TSHRCES2MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015363-B2 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20040181097-A1 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181097-A1 | Process for producing ether compound | CYP2E1, ARL1, MRPL21 | TSHR 4266/4885CES2 95/4885MEN1 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.